AMPK activators as novel therapeutics for type 2 diabetes.
AMPK is a potential target of metabolic diseases including obesity and type 2 diabetes. The activation of AMPK can lead to an increase of glucose uptake into muscle, decreased gluconeogenesis in liver, increased fatty acid oxidation in muscle and liver, decreased fatty acid synthesis in liver and adipose tissue, and increase mitochondrial biogenesis. Until now, many efforts from industrial and academia have been focused on searching novel agents that activate AMPK directly or indirectly. This review will discuss recent advances in the search for novel therapeutic agents that mediate their activity via AMPK activation.
Yu
Li-Fang
LF
Chinese National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guoshoujing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China.
Qiu
Bei-Ying
BY
Nan
Fa-Jun
FJ
Li
Jia
J
D055372:AMP-Activated Protein Kinases / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D008024:Ligands; D008659:Metabolic Diseases / Q000188:drug therapy; D013329:Structure-Activity Relationship
D008024:Ligands; D055372:AMP-Activated Protein Kinases